Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 12, 2024

SELL
$48.48 - $57.85 $91,481 - $109,162
-1,887 Reduced 16.8%
9,342 $479,000
Q3 2023

Nov 13, 2023

SELL
$57.89 - $64.73 $242,038 - $270,636
-4,181 Reduced 27.13%
11,229 $651,000
Q2 2023

Aug 11, 2023

SELL
$63.71 - $70.74 $6,689 - $7,427
-105 Reduced 0.68%
15,410 $985,000
Q1 2023

May 12, 2023

BUY
$65.71 - $74.53 $5,322 - $6,036
81 Added 0.52%
15,515 $1.08 Million
Q4 2022

Feb 14, 2023

SELL
$68.48 - $81.09 $68 - $81
-1 Reduced 0.01%
15,434 $1.11 Million
Q3 2022

Nov 14, 2022

BUY
$0.13 - $76.84 $196 - $116,182
1,512 Added 10.86%
15,435 $1.1 Million
Q2 2022

Aug 12, 2022

BUY
$72.62 - $79.98 $43,354 - $47,748
597 Added 4.48%
13,923 $1.07 Million
Q1 2022

May 12, 2022

SELL
$61.48 - $73.72 $122 - $147
-2 Reduced 0.02%
13,326 $973,000
Q4 2021

Feb 14, 2022

BUY
$53.63 - $62.52 $714,780 - $833,266
13,328 New
13,328 $831,000
Q1 2021

May 17, 2021

SELL
$59.34 - $66.74 $1.12 Million - $1.26 Million
-18,826 Closed
0 $0
Q4 2020

Feb 16, 2021

BUY
$57.74 - $65.43 $174,548 - $197,794
3,023 Added 19.13%
18,826 $1.17 Million
Q3 2020

Nov 16, 2020

SELL
$57.43 - $63.64 $20,387 - $22,592
-355 Reduced 2.2%
15,803 $953,000
Q2 2020

Aug 19, 2020

SELL
$54.82 - $64.09 $103 Million - $121 Million
-1,883,998 Reduced 99.15%
16,158 $950,000
Q2 2020

Aug 13, 2020

BUY
$54.82 - $64.09 $103 Million - $121 Million
1,883,643 Added 11407.03%
1,900,156 $32,000
Q1 2020

May 15, 2020

SELL
$46.4 - $67.43 $237,892 - $345,713
-5,127 Reduced 23.69%
16,513 $920,000
Q4 2019

Feb 14, 2020

BUY
$49.21 - $64.19 $1.06 Million - $1.39 Million
21,640 New
21,640 $1.39 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $125B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Laidlaw Wealth Management LLC Portfolio

Follow Laidlaw Wealth Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Laidlaw Wealth Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Laidlaw Wealth Management LLC with notifications on news.